iPS细胞技术在血液系统疾病中的研究进展及应用  

The Progress and Applications of iPS Cells Technology in Hematopoietic Diseases

作　　者：汪文君[1] 邢文[1] 周圆[1] 杨逢春[1] 

机构地区：[1]中国医学科学院北京协和医学院,血液学研究所血液病医院,实验血液学国家重点实验室,天津300020

出　　处：《中国细胞生物学学报》2014年第11期1567-1572,共6页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:81270575;81170512;81328003)资助的课题~~

摘　　要：诱导性多能干细胞(induced pluripotent stem cells,i PS细胞)是指将一些特定的转录因子转入已分化的成体细胞,使其重编程为形态及功能上类似于胚胎干细胞(embryonic stem cells,ES细胞)的一类细胞。因此,i PS细胞技术避免了传统ES细胞在临床应用方面的道德伦理问题,使其在再生医学、疾病建模、新药筛选等方面具有巨大优势。近年来,i PS细胞技术在血液系统疾病中的研究及应用取得较大突破,包括体外诱导生成造血干/祖细胞、疾病模型的建立及耐药机制的研究、基因治疗单基因遗传病等。该文对i PS细胞诱导重编程技术在血液系统疾病中的最新研究进展进行了综述。Induced pluripotent stem cells（i PS cells） can be directly generated from somatic cells by introducing a defined set of transcription factors.i PS cells exhibit functional and phenotypic similarities to the embryonic stem cells（ES cells）.i PS cells possess less ethical issues as compared to ES cells,and demonstrate significant advantages in regenerative medicine,disease model and drug screening.In recent years,great breakthroughs of i PS cells technology have been made in the field of hematopoietic diseases,including generation of hematopoietic stem/progenitor cells in vitro,establishment of disease models,study of the mechanism of some drug resistance and gene therapy of the monogenic diseases.In this review,we summarized the recent applications and progresses of i PS cells research in hematopoietic diseases.

关 键 词：诱导性多能干细胞 疾病模型 基因治疗 重编程 

分 类 号：R55[医药卫生—血液循环系统疾病]